Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice

Ghasemi, Mehdi; Shafaroodi, Hamed; Nazarbeiki, Saeed; Meskar, Hossein; Heydarpour, Pouria; Ghasemi, Amir; Talab, Saman Shafaat; Ziai, Pouya; Bahremand, Arash; Dehpour, Ahmad Reza

doi:10.1016/j.yebeh.2010.04.002

Cited by 36 publications

(26 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the mood stabilizers studied here, topiramate and lamotrigine reduce glutamate functions by inhibiting glutamate receptors and glutamate release, respectively [52]–[54], which could explain their efficacy. Also treatment with lithium is known to indirectly affect NMDA-type glutamate receptor function, subunit expression and phosphorylation and activation of the related intracellular signalling cascades, such as phospholipase PLA 2 and nitric oxide (NO) pathways [55]–[58], while the NMDA receptor antagonists potentiate the actions of lithium [59]. However, other mechanisms than glutamate antagonism are likely to be involved also, since valproate is not known to antagonize the glutamate system, and indeed valproate has failed to protect from NMDA-induced seizures [60].…”

Section: Discussionmentioning

confidence: 99%

Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice

et al. 2014

View full text Add to dashboard Cite

Abnormal excitatory glutamate neurotransmission and plasticity have been implicated in schizophrenia and affective disorders. Gria1−/− mice lacking GluA1 subunit (encoded by Gria1 gene) of AMPA-type glutamate receptor show robust novelty-induced hyperactivity, social deficits and heightened approach features, suggesting that they could be used to test for anti-manic activity of drugs. Here, we tested the efficacy of chronic treatment with established anti-manic drugs on behavioural properties of the Gria1−/− mice. The mice received standard mood stabilizers (lithium and valproate) and novel ones (topiramate and lamotrigine, used more as anticonvulsants) as supplements in rodent chow for at least 4 weeks. All drugs attenuated novelty-induced locomotor hyperactivity of the Gria1−/− mice, especially by promoting the habituation, while none of them attenuated 2-mg/kg amphetamine-induced hyperactivity as compared to control diet. Treatment with lithium and valproate reversed the elevated exploratory activity of Gria1−/− mice. Valproate treatment also reduced struggling behaviour in tail suspension test and restored reciprocally-initiated social contacts of Gria1−/− mice to the level shown by the wild-type Gria1+/+ mice. Gria1−/− mice consumed slightly more sucrose during intermittent sucrose exposure than the wild-types, but ran similar distances on running wheels. These behaviours were not consistently affected by lithium and valproate in the Gria1−/− mice. The efficacy of various anti-manic drug treatments on novelty-induced hyperactivity suggests that the Gria1−/− mouse line can be utilized in screening for new therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Furthermore, additional modifications of the titled compounds are needed to allow pharmacological investigations of their effects in the central nervous system, e.g., cognitive disorders, as there are considerable evidences that calcium is an important factor for the induction of epilepsy and calcium channel blockers, especially of 1,4-DHP with high lipophilic character, proved to be effective against the whole range of convulsive procedures including electro and Pentylenetetrazole (PTZ) convulsions (Ghasemi et al, 2010;Shafiee et al, 2004). The latter pharmacological investigations are required to prove the potential of titled compounds as an adjuvant, non-sedative antiepileptic drugs, especially in those patients in whom conventional therapy has been inadequate or in patients who are refractory to anticonvulsant treatment, or in cases of untreatable epilepsy.…”

Section: Resultsmentioning

confidence: 99%

“…Specifically, different seizure-inducing agents or procedures cause a rapid intraneuronal influx of calcium ions, which is causally related to the subsequent epileptiform activity (Richard, 2005;Beig et al, 2009;Otoom and Hasan, 2006;Samzadeh-Kermani et al, 2009). Conversely, calcium channel blockers have proven to be effective against the whole range of convulsive procedures including electro and Pentylenetetrazole (PTZ) convulsions (Ghasemi et al, 2010;Shafiee et al, 2004) and sound and high pressure-induced seizures (NGouemo et al, 2010;Luszczki et al, 2008). Previous quantitative structureactivity relationship studies of asymmetric derivatives indicated that the vasodilative as well as the anticonvulsant potency of 1,4-DHPs was dependent upon lipophilic character of the aliphatic substituents located at 3-,4-and 5-position of 1,4-DHPs skeleton (Khoshneviszadeh et al, 2009;Miri et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Calcium Channel Blocking Activity of 1, 4-Dihydropyridine Derivatives Containing Ester Substitute and Phenyl Carbamoyl Group

Sadek¹

2011

American Journal of Applied Sciences

View full text Add to dashboard Cite

Problem statement: Several studies on the synthesis of new nifedipine analogs have been carried out, but the literature reveled that no study on the synthesis and calcium channel blocking activity of the substituted ester with an amide (5-phenylcarbamoyl) moiety has been reported. Approach: Six new derivatives of m-nifedipine have been successfully synthesized by substituting an ester moiety with an amide (5-phenylcarbamoyl) moiety, using a modified Hantzsch reactions and tested for their pharmacological activities. The nifedipine analogs 1-6 were characterized and confirmed using elemental analysis, Infrared spectroscopy (IR), Nuclear Magnetic Resonance ( 1 H NMR) and Mass spectroscopy. The purity of the compounds was ascertained by melting point and TLC. The in vitro calcium channel blocking activities were evaluated using the high K + concentration of Porcine Coronary Artery Smooth Muscles (PCASM) assay. Results: The compounds (1-2) failed to exhibit any blocking activity (IC50 = 10 −7 to 10 −5 M range), while the compounds 3-6 relaxed precontracted porcine coronary artery smooth muscles with pEC50 values ranging between 4.37±0.10 (compound 3) and 6.46±0.07 (compound 5), indicating that compounds 3-6 exhibit comparable potencies in blocking calcium channels to reference drug varapamil (6.97±0.15) and m-nifedipine (6.48±0.05). Conclusion: The results of this study showed that some of the developed new compounds possess maximal calcium channel blocking effects comparable to m-nifedipine. The developed compounds in the present study will predicatively show an increased metabolic stability and consequently longer duration of actions compared to m-nifedipine and could be, therefore, suitable candidates for further optimization to be evaluated as a new class of antihypertensive drugs.

show abstract

“…The drastic clinical improvement obtained with lithium in our patient is particularly interesting. Indeed, unlike antipsychotics, lithium has no deleterious effect on epileptic threshold, and it has even been reported to be protective against seizures 11, 12, 13. It has shown clear efficacy on impulsivity and aggressiveness in a pediatric population 14, 15, 16.…”

Section: Discussionmentioning

confidence: 99%

Lithium improved behavioral and epileptic symptoms in an adolescent with ring chromosome 20 and bipolar disorder not otherwise specified

Inal

Chaumette

Soleimani

et al. 2018

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice

Cited by 36 publications

References 100 publications

Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice

Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice

Synthesis and Calcium Channel Blocking Activity of 1, 4-Dihydropyridine Derivatives Containing Ester Substitute and Phenyl Carbamoyl Group

Lithium improved behavioral and epileptic symptoms in an adolescent with ring chromosome 20 and bipolar disorder not otherwise specified

Contact Info

Product

Resources

About